Design strategies of novel NNRTIs to overcome drug resistance

Current Medicinal Chemistry

Volumn 16, Issue 29, 2009, Pages 3903-3917

  Zhan, Peng ^a   Liu, Xinyong ^a   Li, Zhenyu ^a   Pannecouque, Christophe ^b   De Clercq, Erik ^b  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Drug design; Drug resistance mutations; HIV 1; NNRTIs; RT

Indexed keywords

ANTIVIRUS AGENT; CAPRAVIRINE; CP 94707; DAPIVIRINE; DIHYDROXY BENZOYL NAPHTHYL HYDRAZONE; EMIVIRINE; GCA 186; KM 1; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NUCLEOTIDYLTRANSFERASE INHIBITOR; PYRROLOBENZOXAZEPINONE DERIVATIVE; REVERSE TRANSCRIPTASE INTEGRASE DUAL INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; TRANSFERASE INHIBITOR; TROVIRDINE; UNCLASSIFIED DRUG; VRX 413638;

ANTIVIRAL RESISTANCE; BINDING AFFINITY; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; NONHUMAN; REVERSE TRANSCRIPTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; BENZODIAZEPINES; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HUMANS; IMIDAZOLES; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

EID: 70450184400     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789178019     Document Type: Review

References (113)

1. Tronchet, J.M.; Seman, M. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. Curr. Top Med. Chem., 2003, 3, 1496-1511
2. Martins, S.; Ramos, M.J.; Fernandes, P.A. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr. Med. Chem., 2008, 15, 1083-1095
3. Zhou, Z.; Lin, X.; Madura, J.D. HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development. Infect. Disord. Drug Targets, 2006, 6, 391-413. (Pubitemid 44890632)
4. Seminari, E.; Castagna, A.; Lazzarin, A. Etravirine for the treatment of HIV infection. Expert Rev. Anti Infect. Ther., 2008, 6, 427-433
5. Daar, E.S. Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med., 2008, 16, 110-116
6. Boone, L.R. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Opin. Investig. Drugs, 2006, 7, 128-135 (Pubitemid 43230908)
7. Hsiou, Y.; Ding, J.; Das, K.; Clark, A.D.; Hughes, S.H.; Arnold, E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure, 1996, 4, 853-860 (Pubitemid 26312368)
8. Sarafianos, S.G.; Marchand, B.; Das, K.; Himmel, D.M.; Parniak, M.A.; Hughes, S.H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol., 2009, 385, 693-713.
9. Jochmans, D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res., 2008, 134, 171-185
10. Ilina, T.; Parniak, M.A. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol., 2008, 56, 121-167
11. Zhan, P.; Liu, X.; Li, Z. Recent advances in the discovery and development of novel NNRTI platforms: 2006-2008 update. Curr. Med. Chem., 2009, in press.
12. Ren, J.; Stammers, D.K. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res., 2008, 134, 157-170
13. Sluis-Cremer, N.; Tachedjian, G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res., 2008, 134, 147-156
14. Hopkins, A.L.; Ren, J.; Milton, J.; Hazen, R.J.; Chan, J.H.; Stuart, D.I.; Stammers, D.K. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. J. Med. Chem., 2004, 47, 5912-5922 (Pubitemid 39517015)
15. Freeman, G.A.; Andrews, Iii CW 3rd.; Hopkins, A.L.; Lowell, G.S.; Schaller, L.T.; Cowan, J.R.; Gonzales, S.S.; Koszalka, G.W.; Hazen, R.J.; Boone, L.R.; Ferris, R.G.; Creech, K.L.; Roberts, G.B.; Short, S.A.; Weaver, K.; Reynolds, D.J.; Milton, J.; Ren, J.; Stuart, D.I.; Stammers, D.K.; Chan, J.H. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. J. Med. Chem., 2004, 47, 5923-5936
16. Sarafianos, S.G.; Das, K.; Hughes, S.H.; Arnold, E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol., 2004, 14, 16-30.
17. Barreiro, G.; Guimarães, C.R.; Tubert-Brohman, I.; Lyons, T.M.; Tirado-Rives, J.; Jorgensen, W.L. Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. J. Chem. Inf. Model, 2007, 47, 2416-2428 (Pubitemid 350275106)
18. Schäfer, W.; Friebe, W.G.; Leinert, H.; Mertens, A.; Poll, T.; von der Saal, W.; Zilch, H.; Nuber, B.; Ziegler, M.L. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. J. Med. Chem., 1993, 36, 726-732 (Pubitemid 23105726)
19. Sriram, D.; Bal, T.R.; Yogeeswari, P. Aminopyrimidinimino isatin analogues: design of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. J. Pharm. Pharm. Sci., 2005, 8, 565-577 (Pubitemid 43158124)
20. Sriram, D.; Bal, T.R.; Yogeeswari, P. Newer aminopyrimidinimino isatin analogues as non-nucleoside HIV-1 reverse transcriptase inhibitors for HIV and other opportunistic infections of AIDS: design, synthesis and biological evaluation. FARMACO, 2005, 60, 377-384 (Pubitemid 40725803)
21. Patel, Y.; Gillet, V.J.; Bravi, G.; Leach, A.R. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J. Comput. Aided Mol. Des., 2002, 16, 653-681
22. Daeyaert, F.; de Jonge, M. ; Heeres, J.; Koymans, L.; Lewi, P.; Vinkers, M.H.; Janssen, P.A. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Proteins, 2004, 54, 526-533
23. Daszykowski, M.; Walczak, B.; Xu, Q.S.; Daeyaert, F.; de Jonge, M.R.; Heeres, J.; Koymans, L.M.; Lewi, P.J.; Vinkers, H.M.; Janssen, P.A.; Massart, D.L. Classification and regression trees - studies of HIV reverse transcriptase inhibitors. J. Chem Inf. Comput. Sci., 2004, 44, 716-726
24. Barreca, M.L.; Rao, A.; De Luca, L.; Zappal, M.; Monforte, A.M.; Maga, G.; Pannecouque, C.; Balzarini, J.; De Clercq, E.; Chimirri, A.; Monforte, P. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem., 2005, 48, 3433-3437 (Pubitemid 40628061)
25. Barreca, M.L.; Rao, A.; De Luca, L.; Iraci, N.; Monforte, A.M.; Maga, G.; De Clercq, E.; Pannecouque, C.; Balzarini, J.; Chimirri, A. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg. Med. Chem. Lett., 2007, 17, 1956-1960 (Pubitemid 46367661)
26. Barreca, M.L.; De Luca, L.; Iraci, N.; Rao, A.; Ferro, S.; Maga, G.; Chimirri, A. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J. Chem. Inf. Model, 2007, 47, 557-562 (Pubitemid 46615957)
27. Das, K.; Lewi, P.J.; Hughes, S.H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol., 2005, 88, 209-231
28. Das, K.; Clark, A.D.Jr.; Lewi, P.J.; Heeres, J.; De Jonge, M.R.; Koymans, L.M.; Vinkers, H.M.; Daeyaert, F.; Ludovici, D.W.; Kukla, M.J.; De Corte, B.; Kavash, R.W.; Ho, C.Y.; Ye, H.; Lichtenstein, M.A.; Andries, K.; Pauwels, R.; De Béthune, M.P.; Boyer, P.L.; Clark, P.; Hughes, S.H.; Janssen, P.A.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem., 2004, 47, 2550-2560 (Pubitemid 38580092)
29. Pauwels, R. Aspects of successful drug discovery and development. Antiviral. Res., 2006, 71, 77-89. (Pubitemid 44223771)
30. De Corte, B.L. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4) benzodiazepin-2(1H)- one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem., 2005, 48, 1689-1696
31. Janssen, P.A.; Lewi, P.J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Béthune, M.P.; Pauwels, R.; Das, K.; Clark, A.D.Jr.; Frenkel, Y.V.; Hughes, S.H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino] benzonitrile (R278474, rilpivirine). J. Med. Chem., 2005, 48, 1901-1909 (Pubitemid 40396320)
32. Das, K.; Bauman, J.D.; Clark, A.D.Jr.; Frenkel, Y.V.; Lewi, P.J.; Shatkin, A.J.; Hughes, S.H.; Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U S A, 2008, 105, 1466-1471 (Pubitemid 351346537)
33. Das, K.; Sarafianos, S.G.; Clark, A.D.Jr.; Boyer, P.L.; Hughes, S.H.; Arnold, E. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol., 2007, 365, 77-89. (Pubitemid 44830031)
34. Hsiou, Y.; Das, K.; Ding, J.; Clark, A.D.Jr.; Kleim, J-P.; Roesner, M.; Winkler, I.; Riess, G.; Hughes, S.H.; Arnold, E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol., 1998, 284, 313-323 (Pubitemid 28542456)
35. Ahgren, C.; Backro, K.; Bell, F.W.; Cantrell, A.S.; Clemens, M.; Colacino, J.M.; Deeter, J.B.; Engelhardt, J.A.; Hogberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kasher, J.S.; Kinnick, M.D.; Lind, P.; Lopez, C.; Morin, JR., J.M.; Muesing, M.A.; Noreen, R.; Oberg, B.; Paget, C.J.; Palkowitz, J.A.; Parrish, C.A.; Pranc, P.; Rippy, M.K.; Rydergard, C.; Sahlberg, C.; Swanson, S.; Ternansky, R.J.; Unge, T.; Vasileff, R.T.; Vrang, L.; West, S.J.; Zhang, H.; Zhou, X.-X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 1995, 39, 1329-1335
36. Fujiwara, T.; Sato, A.; el-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L.B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuma, Y. S-1153 inhibits replication of known drugresistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 1998, 42, 1340-1345
37. Ren, J.; Nichols, C.; Bird, L.E.; Fujiwara, T.; Sugimoto, H.; Stuart, D.I.; Stammers, D.K. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem., 2000, 275, 14316-14320
38. Ghosh, A.K.; Chapsal, B.D.; Weber, I.T.; Mitsuya, H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res., 2008, 41, 78-86.
39. Smerdon, S.J.; Jäger, J.; Wang, J.; Kohlstaedt, L.A.; Chirino, A.J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 3911-3915 (Pubitemid 24139542)
40. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D.I.; Stammers, D.K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol., 2001, 312, 795-805.
41. Balzarini, J.; Pelemans, H.; Aquaro, S.; Perno, C.F.; Witvrouw, M.; Schols, D.; De Clercq, E.; Karlsson, A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol., 1996, 50, 394-401. (Pubitemid 26265145)
42. Pelemans, H.; Esnouf, R.; De Clercq, E.; Balzarini, J. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol. Pharmacol., 2000, 57, 954-960 (Pubitemid 30253379)
43. Campiani, G.; Nacci, V.; Fiorini, I.; De Filippis, M.P.; Garofalo, A.; Greco, G.; Novellino, E.; Altamura, S.; Di Renzo, L. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity. J. Med. Chem., 1996, 39, 2672-2680 (Pubitemid 26240334)
44. Campiani, G.; Morelli, E.; Fabbrini, M.; Nacci, V.; Greco, G.; Novellino, E.; Ramunno, A.; Maga, G.; Spadari, S.; Caliendo, G.; Bergamini, A.; Faggioli, E.; Uccella, I.; Bolacchi, F.; Marini, S.; Coletta, M.; Nacca, A.; Caccia, S. Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity. J. Med. Chem., 1999, 42, 4462-4470 (Pubitemid 29504150)
45. Fattorusso, C.; Gemma, S.; Butini, S.; Huleatt, P.; Catalanotti, B.; Persico, M.; De Angelis, M.; Fiorini, I.; Nacci, V.; Ramunno, A.; Rodriquez, M.; Greco, G.; Novellino, E.; Bergamini, A.; Marini, S.; Coletta, M.; Maga, G.; Spadari, S.; Campiani, G. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J. Med. Chem., 2005, 48, 7153-7165 (Pubitemid 41743628)
46. Zanoli, S.; Gemma, S.; Butini, S.; Brindisi, M.; Joshi, B.P.; Campiani, G.; Fattorusso, C.; Persico, M.; Crespan, E.; Cancio, R.; Spadari, S.; Hübscher, U.; Maga, G. Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the "primer grip" region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. Biochem. Pharmacol., 2008, 76, 156-168
47. Butini, S.; Brindisi, M.; Cosconati, S.; Marinelli, L.; Borrelli, G.; Coccone, S.S.; Ramunno, A.; Campiani, G.; Novellino, E.; Zanoli, S.; Samuele, A.; Giorgi, G.; Bergamini, A.; Mattia, M.D.; Lalli, S.; Galletti, B.; Gemma, S.; Maga, G. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. stereoselective interaction to overcome the effects of drug resistant mutations. J. Med. Chem., 2009 Jan 26. on line.
48. Zhan, P.; Li, Z.; Liu, X.; De Clercq, E. Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. Mini. Rev. Med. Chem., 2009, 9, 1014-1023.
49. O'Meara, J.A.; Jakalian, A.; LaPlante, S.; Bonneau, P.R.; Coulombe, R.; Faucher, A.M.; Guse, I.; Landry, S.; Racine, J.; Simoneau, B.; Thavonekham, B.; Yoakim, C. Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3362-3366 (Pubitemid 46819032)
50. Gagnon, A.; Amad, M.H.; Bonneau, P.R.; Coulombe, R.; DeRoy, P.L.; Doyon, L.; Duan, J.; Garneau, M.; Guse, I.; Jakalian, A.; Jolicoeur, E.; Landry, S.; Malenfant, E.; Simoneau, B.; Yoakim, C. Thiotetrazole alkynylacetanilides as potent and bioavailable nonnucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases. Bioorg. Med. Chem. Lett., 2007, 17, 4437-4441 (Pubitemid 47058964)
51. Hopkins, A.L.; Ren, J.; Tanaka, H.; Baba, M.; Okamato, M.; Stuart, D.I.; Stammers, D.K. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J. Med. Chem., 1999, 42, 4500-4505
52. Ren, J.; Stammers, D.K. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. Trends Pharmacol. Sci., 2005, 26, 4-7.
53. Pata, J.D.; Stirtan, W.G.; Goldstein, S.W.; Steitz, T.A. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 10548-10553
54. Hsiou, Y.; Ding, J.; Das, K.; Clark, A.D.; Boyer, P.L.; Lewi, P.; Janssen, P.A.; Kleim, J.P.; Rösner, M.; Hughes, S.H.; Arnold, E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol., 2001, 309, 437-445 (Pubitemid 32564904)
55. Lindberg, J.; Sigurdsson, S.; Löwgren, S; Andersson, H.O.; Sahlberg, C.; Noréen, R.; Fridborg, K.; Zhang, H.; Unge, T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem., 2002, 269, 1670-1677 (Pubitemid 34304466)
56. Himmel, D.M.; Sarafianos, S.G.; Dharmasena, S.; Hossain, M.M.; McCoy-Simandle, K.; Ilina, T.; Clark, A.D.Jr.; Knight, J.L.; Julias, J.G.; Clark, P.K.; Krogh-Jespersen, K.; Levy, R.M.; Hughes, S.H.; Parniak, M.A.; Arnold, E. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem. Biol., 2006, 1, 702-712
57. Zhang, Z.; Walker, M.; Xu, W.; Shim, J.H.; Girardet, J.L.; Hamatake, R.K.; Hong, Z. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunode ficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 2006, 50, 2772-2781 (Pubitemid 44198700)
58. Jochmans, D.; Deval, J.; Kesteleyn, B.; Van Marck, H.; Bettens, E.; De Baere, I.; Dehertogh, P.; Ivens, T.; Van Ginderen, M.; Van Schoubroeck, B.; Ehteshami, M.; Wigerinck, P.; Götte, M.; Hertogs, K. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J. Virol., 2006, 80, 12283-12292 (Pubitemid 44904378)
59. Wang, L.Z.; Kenyon, G.L.; Johnson, K.A. Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1. J. Biol. Chem., 2004, 279, 38424-38432
60. Skillman, A.G.; Maurer, K.W.; Roe, D.C.; Stauber, M.J.; Eargle, D.; Ewing, T.J.; Muscate, A.; Davioud-Charvet, E.; Medaglia, M.V.; Fisher, R.J.; Arnold, E.; Gao, H.Q.; Buckheit, R.; Boyer, P.L.; Hughes, S.H.; Kuntz, I.D.; Kenyon, G.L. A novel mechanism for inhibition of HIV-1 reverse transcriptase. Bioorg. Chem., 2002, 30, 443-458 (Pubitemid 36294220)
61. Basavapathruni, A.; Anderson, K.S. Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly. Curr. Pharm. Des., 2006, 12, 1857-1865
62. Yamazaki, S.; Tan, L.; Mayer, G.; Hartig, J.S.; Song, J.N.; Reuter, S.; Restle, T.; Laufer, S.D.; Grohmann, D.; Kräusslich, H.G.; Bajorath, J.; Famulok, M. Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem. Biol., 2007, 14, 804-812 (Pubitemid 47081421)
63. Camarasa, M.J.; Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J.; Gago, F. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? Antiviral. Res., 2006, 71, 260-267 (Pubitemid 44223776)
64. Camarasa, M.J.; Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J.; Bonache, M.C.; De Castro, S. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress. Curr. Pharm. Des., 2006, 12, 1895-1907
65. Camarasa, M.J.; Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization. Antivir. Chem. Chemother., 2005, 16, 147-153
66. Camarasa, M.J.; San-Félix, A.; Velázquez, S.; Pérez-Pérez, M.J.; Gago, F.; Balzarini, J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top Med. Chem., 2004, 4, 945-963 (Pubitemid 38864692)
67. Bonache, M.C.; Quesada, E.; Sheen, C.W.; Balzarini, J.; Sluis- Cremer, N.; Pérez-Pérez, M.J.; Camarasa, M.J.; San-Félix, A. Novel N-3 substituted TSAO-T derivatives: synthesis and anti- HIV-evaluation. Nucleosides Nucleotides Nucleic Acids, 2008, 27, 351-367
68. Tomassi, C.; Nguyen, V.N.; Marco-Contelles, J.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Soriano, E.; Postel, D. Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound. Bioorg. Med. Chem. Lett., 2008, 18, 2277-2281
69. Tomassi, C.; Nguyen Van Nhien, A.; Marco-Contelles, J.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Postel, D. Synthesis and anti-HIV1 biological activity of novel 5″-ATSAO compounds. Bioorg. Med. Chem., 2008, 16, 4733-4741 (Pubitemid 351539016)
70. de Castro, S.; Andrei, G.; Snoeck, R.; Balzarini, J.; Camarasa, M.J.; Velázquez, S. Novel non-nucleoside human cytomegalovirus inhibitors based upon TSAO nucleoside derivatives: structureactivity relationships. Nucleosides Nucleotides Nucleic Acids, 2007, 26, 625-628 (Pubitemid 350239245)
71. Sluis-Cremer, N.; Hamamouch, N.; San Félix, A.; Velazquez, S.; Balzarini, J.; Camarasa, M.J. Structure-activity relationships of [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl] -3′-spiro -5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. J. Med. Chem., 2006, 49, 4834-4841 (Pubitemid 44202171)
72. Soriano, E.; Marco-Contelles, J.; Tomassi, C.; Nguyen Van Nhien, A.; Postel, D. Computational analysis of aza analogues of [2′,5′-bis- O-(tert-butyldimethylsilyl)-beta-D- ribofuranose]-3′-spiro-5″- (4″- amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity. J. Chem. Inf. Model, 2006, 46, 1666-1677 (Pubitemid 44185693)
73. de Castro, S.; García-Aparicio, C.; Van Laethem, K.; Gago, F.; Lobatón, E.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.; Velázquez, S. Discovery of TSAO derivatives with an unusual HIV-1 activity/ resistance profile. Antiviral. Res., 2006, 71, 15-23. (Pubitemid 44202207)
74. Bonache, M.C.; Chamorro, C.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Barrios, F.R.; Gago, F.; Camarasa, M.J.; San-Félix, A. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J. Med. Chem., 2005, 48, 6653-6660 (Pubitemid 41509181)
75. Nguyen Van Nhien, A.; Tomassi, C.; Len, C.; Marco-Contelles, J.L.; Balzarini, J.; Pannecouque, C.; De Clercq, E.; Postel, D. First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication. J. Med. Chem., 2005, 48, 4276-4284 (Pubitemid 40884931)
76. Bonache, M.C.; Chamorro, C.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.; San-Félix, A. N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase. Nucleosides Nucleotides Nucleic Acids, 2003, 22, 947-949 (Pubitemid 37139297)
77. Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Pérez- Pérez, M.J.; Camarasa, M.J.; Pelemans, H.; Balzarini, J.; Gago, F. Identification of a putative binding site for [2′,5′-bis-O-(tert- butyldimethylsilyl)-beta-Dribofuranosyl]- 3′-spiro-5″-(4″- amino-1″,2″-oxathiole-2″,2″-dioxide) thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem., 2001, 44, 1853-1865 (Pubitemid 32888185)
78. Sluis-Cremer, N.; Arion, D.; Parniak, M.A. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol., 2002, 62, 398-405.
79. Grohmann, D.; Corradi, V.; Elbasyouny, M.; Baude, A.; Horenkamp, F.; Laufer, S.D.; Manetti, F.; Botta, M.; Restle, T. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. Chembiochem, 2008, 9, 916-922
80. Balzarini, J.; Auwerx, J.; Rodríguez-Barrios, F.; Chedad, A.; Farkas, V.; Ceccherini-Silberstein, F.; García-Aparicio, C.; Velázquez, S.; De Clercq, E.; Perno, C.F.; Camarasa, M.J.; Gago, F. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors. Mol. Pharmacol., 2005, 68, 49-60. (Pubitemid 41007052)
81. Mulky, A.; Vu, B.C.; Conway, J.A.; Hughes, S.H.; Kappes, J.C. Analysis of amino acids in the β7-β8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication. J. Mol. Biol., 2007, 365, 1368-1378 (Pubitemid 46061425)
82. Zhou, Z.; Madrid, M.; Evanseck, J.D.; Madura, J.D. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. J. Am. Chem. Soc., 2005, 127, 17253-17260
83. Grob, P.M.; Wu, J.C.; Cohen, K.A.; Ingraham, R.H.; Shih, C.K.; Hargrave, K.D.; McTague, T.L.; Merluzzi, V.J. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses, 1992, 8, 145-152
84. Klunder, J.M.; Hoermann, M.; Cywin, C.L.; David, E.; Brickwood, J.R.; Schwartz, R.; Barringer, K.J.; Pauletti, D.; Shih, C.K.; Erickson, D.A.; Sorge C.L.; Joseph, D.P.; Hattox, S.E.; Adams, J.; Grob, P.M. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broadspectrum inhibitors of wild-type and mutant enzymes. J. Med. Chem., 1998, 41, 2960-2971
85. Cywin, C.L.; Klunder, J.M.; Hoermann, M.; Brickwood, J.R.; David, E.; Grob, P.M.; Schwartz, R.; Pauletti, D.; Barringer, K.J.; Shih, C.K.; Sorge, C.L.; Erickson, D.A.; Joseph, D.P.; Hattox, S.E. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8- arylthiomethyldipyridodiazepinones. J. Med. Chem., 1998, 41, 2972-2984 (Pubitemid 28359932)
86. Yoakim, C.; Bonneau, P.R.; Déziel, R.; Doyon, L.; Duan, J.; Guse, I.; Landry, S.; Malenfant, E.; Naud, J.; Ogilvie, W.W.; O'Meara, J.A.; Plante, R.; Simoneau, B.; Thavonekham, B.; Bös, M.; Cordingley, M.G. Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 739-742 (Pubitemid 38114863)
87. O'Meara, J.A.; Yoakim, C.; Bonneau, P.R.; Bös, M.; Cordingley, M.G.; Déziel, R.; Doyon, L.; Duan, J.; Garneau, M.; Guse, I.; Landry, S.; Malenfant, E.; Naud, J.; Ogilvie, W.W.; Thavonekham, B.; Simoneau, B. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors. J. Med. Chem., 2005, 48, 5580-5588 (Pubitemid 41209255)
88. Coulombe, R.; Fink, D.; Landry, S.; Lessard, I.A.D.; McCollum, R.; Naud, J.; O'Meara, J.; Simoneau, B.; Yoakim, C.; Bonneau, P.R. Crystallographic study with BILR 355 BS, A novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro-July 24-27, 2005.
89. Sweeney, Z.K.; Harris, S.F.; Arora, N.; Javanbakht, H.; Li, Y.; Fretland, J.; Davidson, J.P.; Billedeau, J.R.; Gleason, S.K.; Hirschfeld, D.; Kennedy-Smith, J.J.; Mirzadegan, T.; Roetz, R.; Smith, M.; Sperry, S.; Suh, J.M.; Wu, J.; Tsing, S.; Villasenor, A.G.; Paul, A.; Su, G.; Heilek, G.; Hang, J.Q.; Zhou, A.S.; Jernelius, J.A.; Zhang, F.J.; Klumpp, K. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. J. Med. Chem., 2008, 51, 7449-7458
90. Ren, J.; Milton, J.; Weaver, K.L.; Short, S.A.; Stuart, D.I.; Stammers, D.K. Structural basis for the resilience of efavirenz (DMP- 266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure, 2000, 8, 1089-1094
91. Griffith, R.; Luu, T.T.; Garner, J.; Keller, P.A. Combining structure-based drug design and pharmacophores. J. Mol. Graph Model, 2005, 23, 439-446 (Pubitemid 40386873)
92. D'Cruz, O.J.; Uckun, F.M. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Enzyme Inhib. Med. Chem., 2006, 21, 329-350 (Pubitemid 44355782)
93. D'Cruz, O.J.; Uckun, F.M. Novel broad-spectrum thiourea nonnucleoside inhibitors for the prevention of mucosal HIV transmission. Curr. HIV Res., 2006, 4, 329-345
94. Vig, R.; Mao, C.; Venkatachalam, T.K.; Tuel-Ahlgren, L.; Sudbeck, E.A.; Uckun, F.M. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent nonnucleoside inhibitors of HIV reverse transcriptase. Bioorg. Med. Chem., 1998, 6, 1789-1797 (Pubitemid 28524233)
95. Mao, C.; Vig, R.; Venkatachalam, T.K.; Sudbeck, E.A.; Uckun, F.M. Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5- bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)] -N′-[2-(5- bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett., 1998, 8, 2213-2218
96. Vig, R.; Mao, C.; Venkatachalam, T.K.; Tuel-Ahlgren, L.; Sudbeck, E.A.; Uckun, F.M. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent nonnucleoside inhibitors of HIV reserve transcriptase. Bioorg. Med. Chem., 1998, 6, 1789-1797
97. Mao, C.; Sudbeck, E.A.; Venkatachalam, T.K.; Uckun, F.M. Structure-based drug design of non-nucleoside inhibitors for wildtype and drug-resistant HIV reverse transcriptase. Biochem. Pharmacol., 2000, 60, 1251-1265
98. Vig, R.; Mao, C. Nonnucleoside inhibitors of reverse transcriptase, composite binding pocket and methods for use thereof. WO9947501A (1999); US6380190B (2002); US2005153995A (2005).
99. Esnouf, R.M.; Ren, J.; Hopkins, A.L.; Ross, C.K.; Jones, E.Y.; Stammers, D.K.; Stuart, D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 3984-3989
100. Hopkins, A.L.; Ren, J.; Esnouf, R.M.; Willcox, B.E.; Jones, E.Y.; Ross, C.; Miyasaka, T.; Walker, R.T.; Tanaka, H.; Stammers, D.K.; Stuart, D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem., 1996, 39, 1589-1600 (Pubitemid 26124233)
101. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543 (Pubitemid 41504710)
102. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651 (Pubitemid 38981718)
103. Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem., 2006, 49, 4961-4970 (Pubitemid 44201054)
104. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today, 2007, 12, 156-160
105. Morphy, R.; Rankovic, Z. Designing Multiple Ligands-Medicinal Chemistry Strategies and Challenges. Curr. Pharm. Des., 2009, 15, 587-600.
106. Zhan, P.; Liu, X. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des., 2009, 15, 1893-1917
107. Wang, Z.; Bennett, E.M.; Wilson, D.J.; Salomon, C.; Vince, R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J. Med. Chem., 2007, 50, 3416-3419 (Pubitemid 47195448)
108. Wang, Z.; Vince, R. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. Bioorg. Med. Chem. Lett., 2008, 1118, 1293-1296 (Pubitemid 351226545)
109. Wang, Z.; Vince, R. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. Bioorg. Med. Chem., 2008, 16, 3587-3595
110. Tucker, T.J.; Saggar, S.; Sisko, J.T.; Tynebor, R.M.; Williams, T.M.; Felock, P.J.; Flynn, J.A.; Lai, M.T.; Liang, Y.; McGaughey, G.; Liu, M.; Miller, M.; Moyer, G.; Munshi, V.; Perlow-Poehnelt, R.; Prasad, S.; Sanchez, R.;
111. Sweeney, Z.K.; Kennedy-Smith, J.J.; Wu, J.; Arora, N.; Billedeau, J.R.; Davidson, J.P.; Fretland, J.; Hang, J.Q.; Heilek, G.M.; Harris, S.F.; Hirschfeld, D.; Inbar, P.; Javanbakht, H.; Jernelius, J.A.; Jin, Q.; Li, Y.; Liang, W.; Roetz, R.; Sarma, K.; Smith, M.; Stefanidis, D.; Su, G.; Suh, J.M.; Villaseñor, A.G.; Welch, M.; Zhang, F.J.; Klumpp, K. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties. ChemMedChem, 2008, 4, 88-99.
112. rd.; Stammers, D.K.; Hazen, R.J.; Ferris, R.G.; Short, S.A.; Chan, J.H.; Boone, L.R. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J. Med. Chem., 2006, 49, 727-739
113. Ren, J.; Chamberlain, P.P.; Stamp, A.; Short, S.A.; Weaver, K.L.; Romines, K.R.; Hazen, R.; Freeman, A.; Ferris, R.G.; Andrews, C.W.; Boone, L.; Chan, J.H.; Stammers, D.K. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem., 2008, 51, 5000-5008